Share

Tempus AI, Inc. Common Stock (TEM.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 21 September 2026Deep analysis 21 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Neutral

5-Year Return Est.

+35.1%

TEM.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is arithmetic, not narrative. Tempus has genuinely crossed from cash-burning data experiment to scaled diagnostics platform — Q2 2026 brought $382.5 million revenue, first GAAP net income and positive adjusted EBITDA — yet growth decelerated from 83% to 22% while the September re-rating to 9.9x sales already borrowed the 2027 margin bridge [1][7]. Base case: Personalis closes, ADLT pricing lifts 2027, climbs toward the low twenties by 2030, but multiple compression consumes most of that fundamental progress. Investors collect mid-single-digit annualised returns along a violently uneven path.

FY2026 guidance of $1.595-1.605 billion with ~$65 million implies roughly 225x EV/EBITDA today.
Assume $4.0 billion 2031 revenue at 22% ; 18x on ~215 million shares approximates $105.
Cross-check: that $20 billion equity equals about 5x 2031 sales, still premium to mature diagnostics comparables.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2024-06-14	40.3
Observed price	2024-06-22	27.5
Observed price	2024-06-26	27.6
Observed price	2024-06-30	33.9
Observed price	2024-07-08	33.2
Observed price	2024-07-16	40.7
Observed price	2024-07-24	38.0
Observed price	2024-07-28	43.2
Observed price	2024-08-01	39.3
Observed price	2024-08-05	38.2
Observed price	2024-08-13	42.6
Observed price	2024-08-21	71.5
Observed price	2024-08-25	62.0
Observed price	2024-09-02	53.9
Observed price	2024-09-10	45.0
Observed price	2024-09-14	51.1
Observed price	2024-09-18	51.3
Observed price	2024-09-22	55.0
Observed price	2024-09-30	56.6
Observed price	2024-10-08	48.1
Observed price	2024-10-12	49.5
Observed price	2024-10-20	48.9
Observed price	2024-10-24	46.2
Observed price	2024-10-28	43.3
Observed price	2024-11-05	44.5
Observed price	2024-11-09	75.1
Observed price	2024-11-21	52.5
Observed price	2024-11-25	63.9
Observed price	2024-11-29	62.6
Observed price	2024-12-07	49.1
Observed price	2024-12-11	43.2
Observed price	2024-12-19	33.0
Observed price	2024-12-27	35.1
Observed price	2024-12-31	33.8
Observed price	2025-01-04	39.1
Observed price	2025-01-12	34.1
Observed price	2025-01-16	34.8
Observed price	2025-01-24	51.4
Observed price	2025-01-28	51.0
Observed price	2025-02-05	69.2
Observed price	2025-02-09	68.6
Observed price	2025-02-17	83.8
Observed price	2025-02-21	68.1
Observed price	2025-03-01	54.4
Observed price	2025-03-05	53.1
Observed price	2025-03-13	42.2
Observed price	2025-03-17	49.9
Observed price	2025-03-25	58.6
Observed price	2025-04-02	49.9
Observed price	2025-04-06	42.7
Observed price	2025-04-10	40.3
Observed price	2025-04-14	43.1
Observed price	2025-04-22	43.2
Observed price	2025-04-26	53.2
Observed price	2025-05-04	55.1
Observed price	2025-05-08	65.2
Observed price	2025-05-16	65.5
Observed price	2025-05-20	62.4
Observed price	2025-05-28	53.2
Observed price	2025-06-01	60.7
Observed price	2025-06-09	66.9
Observed price	2025-06-13	71.3
Observed price	2025-06-21	67.4
Observed price	2025-06-29	64.5
Observed price	2025-07-03	61.0
Observed price	2025-07-11	56.9
Observed price	2025-07-15	55.9
Observed price	2025-07-23	64.9
Observed price	2025-07-27	62.8
Observed price	2025-07-31	56.6
Observed price	2025-08-08	60.9
Observed price	2025-08-16	75.3
Observed price	2025-08-20	73.3
Observed price	2025-08-24	77.4
Observed price	2025-09-01	77.7
Observed price	2025-09-09	81.0
Observed price	2025-09-13	86.0
Observed price	2025-09-21	86.7
Observed price	2025-09-25	77.3
Observed price	2025-10-03	91.7
Observed price	2025-10-11	95.8
Observed price	2025-10-15	91.9
Observed price	2025-10-23	87.0
Observed price	2025-10-27	91.6
Observed price	2025-10-31	89.8
Observed price	2025-11-08	71.6
Observed price	2025-11-12	71.1
Observed price	2025-11-20	65.7
Observed price	2025-11-28	77.9
Observed price	2025-12-02	74.0
Observed price	2025-12-06	76.8
Observed price	2025-12-14	69.3
Observed price	2025-12-18	62.2
Observed price	2025-12-22	65.9
Observed price	2025-12-30	60.4
Observed price	2026-01-07	69.8
Observed price	2026-01-15	68.9
Observed price	2026-01-19	67.7
Observed price	2026-01-27	66.8
Observed price	2026-01-31	59.4
Observed price	2026-02-08	56.4
Observed price	2026-02-12	50.8
Observed price	2026-02-16	52.4
Observed price	2026-02-20	58.4
Observed price	2026-02-28	53.3
Observed price	2026-03-04	51.3
Observed price	2026-03-16	50.9
Observed price	2026-03-20	47.0
Observed price	2026-03-24	48.8
Observed price	2026-03-28	42.5
Observed price	2026-04-05	47.3
Observed price	2026-04-09	44.2
Observed price	2026-04-17	55.9
Observed price	2026-04-25	52.3
Observed price	2026-05-03	55.5
Observed price	2026-05-07	49.5
Observed price	2026-05-11	48.5
Observed price	2026-05-15	43.9
Observed price	2026-05-23	46.3
Observed price	2026-05-31	52.0
Observed price	2026-06-04	52.3
Observed price	2026-06-12	47.8
Observed price	2026-06-20	49.3
Observed price	2026-06-24	51.9
Observed price	2026-06-28	57.6
Observed price	2026-07-06	60.7
Observed price	2026-07-14	58.7
Observed price	2026-07-18	51.1
Observed price	2026-07-22	47.0
Observed price	2026-07-26	42.8
Observed price	2026-08-03	46.0
Observed price	2026-08-11	55.7
Observed price	2026-08-15	51.9
Observed price	2026-08-23	68.3
Observed price	2026-08-27	70.7
Observed price	2026-08-31	63.0
Observed price	2026-09-12	60.1
Observed price	2026-09-16	70.0
Observed price	2026-09-21	78.0
Observed price	2026-09-23	76.6
Observed price	2026-09-24	82.2
Observed price	2026-09-25	85.0
Published advisor forecast	2026-09-18	77.8
Published advisor forecast	2026-12-18	69.3
Published advisor forecast	2027-03-18	65.1
Published advisor forecast	2027-06-18	70.3
Published advisor forecast	2027-09-18	73.8
Published advisor forecast	2027-12-18	78.3
Published advisor forecast	2028-03-18	74.4
Published advisor forecast	2028-06-18	78.8
Published advisor forecast	2028-09-18	82.8
Published advisor forecast	2028-12-18	86.1
Published advisor forecast	2029-03-18	88.7
Published advisor forecast	2029-06-18	83.3
Published advisor forecast	2029-09-18	88.3
Published advisor forecast	2029-12-18	91.9
Published advisor forecast	2030-03-18	94.6
Published advisor forecast	2030-06-18	96.5
Published advisor forecast	2030-09-18	91.7
Published advisor forecast	2030-12-18	97.2
Published advisor forecast	2031-03-18	100
Published advisor forecast	2031-06-18	102
Published advisor forecast	2031-09-18	105

2. Scenarios & Signals

Bull case

The bull case activates when reimbursement and data monetisation arrive together rather than sequentially. Broadened MolDX coverage pushes NeXT Personal volumes through Tempus's existing hospital channel, MRD revenue quadruples, and the 100,000-genome library converts into nine-figure pharma licences at software margins. Consolidated growth reaccelerates above 25% with EBITDA margin near 30%, and the multiple expands rather than compresses because mix shifts toward recurring data revenue. The share price roughly doubles from here.

Bear case

The bear case activates when decelerating growth meets a reimbursement cut. Q3 and Q4 2026 print near 20%, the guided second-half reacceleration fails, and analysts who chased targets above spot reverse hard. Personalis integration consumes management attention while Signatera defends share on price; a 2028 PAMA reset then erases the ADLT uplift. Goodwill exceeding tangible equity forces a write-down, and a 3.7-beta stock with no earnings floor retraces toward its $36 low.

Current crowd narrative

The tape treats Tempus as the proven AI-in-healthcare winner: a first GAAP-profitable quarter, a transformational MRD acquisition and a 54% one-month gain have hardened into settled fact [1]. The anchoring bias is stark — consensus targets of $62-68 now sit below spot, meaning the crowd is pricing upgrades that have not yet been written, not fundamentals already delivered [19][20].

Alpha-gap assessment

The crowd overestimates these shares at $77.80 — modestly overpriced, not absurdly so. The overlooked evidence is arithmetic: market capitalisation roughly doubled from $7.48 billion in July to $14.2 billion in September without any change to FY2026 guidance [9]. That is pure multiple expansion borrowing the 2027 margin bridge in advance. The blind spot is the exchange-ratio reflexivity: the rally mechanically cheapens Personalis, which sell-side then cites as accretion, which justifies the rally. Circular logic, genuine business.

Convergence catalyst

Q3 2026 results, due late October, are the first clean read on whether the guided second-half reacceleration to roughly 24% is real or arithmetic. A print near 22% with unchanged guidance breaks the upgrade cycle. First observable sign: analysts trimming rather than chasing targets.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.5
Expected volatility regime: high_erratic
Convergence-cycle position: momentum

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Fixed COST BASE Finally Bends	The operating margin moved from -99.7% in FY2024 to -19.88% in FY2025, and Q2 2026 produced $5.6 million of GAAP net income with $8.0 million adjusted EBITDA against $(42.8) million a year earlier [7]. Sequencing and bioinformatics costs are largely fixed; each incremental test and data query drops through. Management guides to adjusted EBITDA and free cash flow positive in 2027, which the evidence now supports.	Not available	+22.0%
ADLT Pricing Unlocks Tumor ONLY XT	FDA approval of tumor-only xT CDx permits unified Advanced Diagnostic Laboratory Test pricing, which management estimates adds roughly $85 million of annualised revenue from 2027 [8]. Because the incremental dollars land on tests already being run, flow-through to gross profit approaches full margin — the cleanest earnings lever in the model. It persists as long as CMS maintains ADLT status, reset annually against market rate.	Not available	+18.0%
DATA Flywheel Outgrows THE LAB	Data and Applications grew 28% in Q2 2026 versus 20% for Diagnostics, and the September initiative to assemble 100,000 linked whole genomes — targeting one million — extends the only genuinely defensible asset here [5][7]. Pharma pays recurring, high-margin licence fees for longitudinal multimodal data that cannot be replicated quickly. This mix shift raises blended gross margin and justifies a software-adjacent multiple component.	Not available	+15.0%
ZERO Coupon Money IN A 5% World	Tempus completed a $460 million 0.0% convertible senior notes offering due 2032, saving over $30 million of annual interest against comparable straight debt while the US 10-year sits near 5% [8]. Combined with $820.7 million of cash and marketable securities at June 2026, this removes near-term financing coercion and lets management fund Personalis integration without a distressed equity raise. The option cost is deferred dilution.	Not available	+8.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Growth Decays While Multiple Stays	Revenue growth fell from +83.4% in FY2025 — inflated by the Ambry acquisition — to +36.1% in Q1 2026 and +22% in Q2, with acquired hereditary cancer testing decelerating to 5% year-over-year [7][8]. At 9.9x TTM sales the security is priced for durable thirty-percent compounding. A Rule-of-40 score near 24 cannot support that multiple indefinitely; compression is the most probable single drag over five years.	Not available	-26.0%
FIVE Percent Discounts Distant CASH	The US 10-year closed at 4.998% on 18 September 2026 with the Fed at 3.75%-4.00% and the median dot implying another hike. Essentially all of Tempus's value sits in 2029-2031 cash flows; with a reported beta between 3.7 and 5.2, each 50 basis points of term premium removes a disproportionate slice of present value [1][2]. Persistent energy-driven inflation keeps this headwind engaged.	Not available	-18.0%
Stock Based Compensation AS Hidden TAX	The first GAAP profit of $5.6 million sat alongside $54.1 million of quarterly stock-based compensation and negative $7.5 million operating cash flow [1][8]. TTM free cash flow remains -$273 million. Share count grows structurally, and the all-stock Personalis consideration adds roughly 17-28 million shares depending on the exchange ratio [10]. Per-share economics therefore improve far more slowly than headline EBITDA implies.	Not available	-15.0%
Signatera OWNS THE MRD Beachhead	Personalis brings four Medicare-covered indications and 1,400 ordering physicians, but Natera's Signatera is entrenched with far larger volumes, and Guardant and Exact Sciences are funding competing molecular residual disease assays [15]. Paying roughly 15x sales for a loss-making challenger invites a price war in a PAMA-governed reimbursement regime. Expect slower-than-modelled MRD revenue capture and first-year dilution to consolidated EBITDA.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
MRD Reimbursement Breakout	If MolDX broadens coverage for NeXT Personal across additional solid tumours during 2027-2028 and Tempus channels the assay through its existing hospital connectivity and 45% algorithm attach base, MRD could scale from a ~$90 million run-rate toward $400 million at diagnostics-grade margins [9][14]. That would restore consolidated growth above 25% and re-rate the data segment alongside it. It stays below even odds because coverage decisions are indication-by-indication, Signatera holds the clinical-evidence lead, and PAMA rate resets cut the other way.	30.0%	+62.0%
Pharma PAYS FOR THE Genome Library	The 100,000-genome initiative reaches general availability in mid-2027 [5][6]. A multi-year, nine-figure licensing framework with two or three large pharmaceutical sponsors — or an AI-model developer seeking clinically grounded training corpora — would convert an unpriced announcement into recurring, ~80% gross-margin revenue and justify a software multiple on a third of the business. Probability stays under half because the September announcement disclosed no contract value, and pharma R&D budgets face their own cost discipline through 2027-2028.	26.0%	+45.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
PAMA RATE Reset GUTS THE CORE	Advanced Diagnostic Laboratory Test status is repriced annually against reported market rates, and the broader Clinical Laboratory Fee Schedule faces repeated legislative deferral fights. A 2028-2029 reset that cuts xT or Ambry hereditary panel reimbursement by 15-20% would erase the entire $85 million ADLT uplift and push the 2027 free-cash-flow commitment out by years, collapsing the multiple on a business with no earnings cushion [8]. Probability sits below half because Congress has repeatedly delayed PAMA cuts.	28.0%	-42.0%
Goodwill Meets Reality	Consolidated equity was $491 million at end-2025 against a price-to-book of 31.9; adding roughly $1.5 billion of Personalis purchase price on top of Ambry goodwill creates an impairment surface far larger than tangible net worth. If MRD volumes disappoint through 2028 and a non-cash write-down lands alongside a covenant or convertible-refinancing conversation, the equity story shifts from compounding platform to balance-sheet repair [10]. Below fifty percent because cash of $820.7 million buys considerable time.	24.0%	-38.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_8f6f0bf5-d7ee-50df-b5ed-8966e7e8b8e0__sb7__20260921000009996347
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-11.0%	69.28	Momentum unwinds as Q3 results in late October show roughly 22% growth against a guided second-half reacceleration. Consensus targets already sit below spot; a 5% 10-year compounds the de-rating of distant cash flows.
2	March 18, 2027	-6.0%	65.12	Personalis closes and share issuance lands, diluting per-share metrics while first-year MRD losses consolidate. FY2027 guidance including the target disappoints on EBITDA, and January tax-loss rebound fades quickly.
3	June 18, 2027	+8.0%	70.33	Unified ADLT pricing on tumor-only xT flows through Q1 reporting, adding near-full-margin revenue. Evidence of the promised free-cash-flow crossover restores confidence and draws growth capital back into profitable diagnostics names.
4	September 18, 2027	+5.0%	73.85	General availability of the whole-genome research platform arrives mid-2027, converting an unpriced announcement into early licence bookings. Data and Applications outgrowing Diagnostics supports incremental multiple, offset by continued stock-compensation dilution.
5	December 18, 2027	+6.0%	78.28	Full-year 2027 tracks toward the first positive free-cash-flow year. Easing inflation allows the Fed to pause, compressing term premium and mechanically lifting valuations of long-duration healthcare technology equities.
6	March 18, 2028	-5.0%	74.36	Integration costs and Signatera price competition surface in Q4 reporting, capping MRD margin expectations. Guidance for 2028 growth near 18% underwhelms investors anchored to the acquisition-inflated growth narrative.
7	June 18, 2028	+6.0%	78.83	Operating leverage becomes visible as gross margin approaches the high sixties and fixed bioinformatics costs spread across higher volumes. EBITDA margin crossing ten percent shifts the valuation debate from sales to earnings.
8	September 18, 2028	+5.0%	82.77	Additional MolDX indication coverage for NeXT Personal broadens the reimbursable MRD market. Pharma data renewals demonstrate recurring revenue durability, lifting the quality of the revenue mix investors are paying for.
9	December 18, 2028	+4.0%	86.08	Positive free cash flow for a full year removes financing overhang and dilution fears. However, decelerating headline growth near seventeen percent keeps the multiple anchored rather than expanding further.
10	March 18, 2029	+3.0%	88.66	Steady execution with 2029 guidance in line. Convertible notes due 2032 begin entering refinancing discussion, a modest overhang balanced by accumulated cash and improved credit standing.
11	June 18, 2029	-6.0%	83.34	A PAMA reimbursement rate review cycle reprices advanced diagnostic tests downward, trimming forward revenue estimates. Sector-wide multiple compression across molecular diagnostics amplifies the company-specific estimate cut.
12	September 18, 2029	+6.0%	88.34	Management offsets rate pressure with volume growth and cost discipline, and the data segment's insensitivity to reimbursement becomes an explicit part of the equity story. Estimates stabilise and the stock recovers.
13	December 18, 2029	+4.0%	91.87	Approaching three billion dollars of revenue with mid-teens EBITDA margin, the company screens as a profitable compounder rather than a speculative platform. Index and generalist ownership broadens the shareholder base.
14	March 18, 2030	+3.0%	94.63	Full-year results confirm the margin trajectory. Growth settling near fifteen percent means returns now come from earnings accretion rather than re-rating, producing steady but unspectacular appreciation.
15	June 18, 2030	+2.0%	96.52	Competitive intensity in MRD and comprehensive genomic profiling caps pricing. Incremental gains depend on algorithm monetisation finally converting the attach rate into billable revenue, a slow-moving reimbursement process.
16	September 18, 2030	-5.0%	91.70	A broader risk-off episode in high-multiple healthcare technology, triggered by renewed rate volatility or a disappointing sector print, hits a still-elevated beta name harder than the index.
17	December 18, 2030	+6.0%	97.20	Recovery as 2031 guidance shows EBITDA margin approaching twenty percent and genuine free-cash-flow yield emerges. Buyback capacity becomes plausible for the first time, changing the per-share arithmetic.
18	March 18, 2031	+3.0%	100.12	Mature-platform valuation logic dominates: earnings growth plus modest share-count discipline drive returns. Convertible refinancing completes without meaningful dilution, removing a long-standing structural concern.
19	June 18, 2031	+2.0%	102.12	Steady execution against a roughly four-billion-dollar revenue base. Upside now requires a new therapeutic-area or geographic expansion; absent that, the stock tracks earnings growth closely.
20	September 18, 2031	+3.0%	105.18	Horizon close with the company established as a profitable precision-medicine platform. Cumulative five-year appreciation near forty percent reflects real earnings progress largely offset by the multiple compression from today's extended entry price.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook - 24/7 Wall St.247wallst.com
[2]Free Trialmarketbeat.com
[3]Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum - StocksToTradestockstotrade.com
[4]TEM Stock Quote Price and Forecast | CNNcnn.com
[5]Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-driven Healthcare Innovationtempus.com
[6]Tempus AI Building Multimodal Whole-Genome Dataset for AI Research | Bitget Newsbitget.com
[7]Tempus AI posts Q2 profit on 22% revenue growth | TEM 8-K Filingstocktitan.net
[8]Tempus AI Inc (TEM) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% to $382. ...finance.yahoo.com
[9]Earnings call transcript: Tempus AI beats Q2 2026 EPS view as stock trims gains By Investing.cominvesting.com
[10]Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platformtempus.com
[11]Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform | Tempus AIinvestors.tempus.com
[12]Personalis, Inc. - Form 425 - FY2026sec.gov
[13]Tempus AI (NasdaqGS:TEM) Stock Forecast & Analyst Predictions - Simply Wall Stsimplywall.st
[14]Personalis, Inc. - Form 425 - FY2026sec.gov
[15]Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliantfinance.yahoo.com
[16]Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billionfinance.yahoo.com
[17]Tempus AI Bets on MRD Testing Growth With Personalis Acquisitionfinance.yahoo.com
[18]Tempus AI (TEM) Extends Rally After Earnings Beat And $1.5B Deal - StocksToTradestockstotrade.com
[19]Tempus AI (TEM) Stock Price & Overviewstockanalysis.com
[20]Tempus AI (TEM) Stock Forecast & Analyst Price Targetsstockanalysis.com
[21]Tempus AI (Nasdaq:TEM) - Stock Analysis - Simply Wall Stsimplywall.st
[22]Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Aligntimothysykes.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Superintelligence — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.